Cytophage Technologies Ltd. Completes Reverse Takeover and Listing on TSX Venture Exchange
Cytophage Technologies Ltd. (“Cytophage”), formerly Cuspis Capital III Ltd., has completed a reverse take-over (the “RTO”) of Cytophage Technologies Inc. (“CTI”), a privately held biotechnology company existing under the laws of the Province of Manitoba, by way a three-cornered amalgamation. CTI is a biotechnology company dedicated to innovative bacteriophage research, product development and commercialization to address the global challenge of antibiotic resistance and combat bacterial infections affecting human health, animal health, and food security.
Trading of the common shares of Cytophage commenced on the TSX Venture Exchange on February 9, 2024 under the symbol “CYTO”.
Wildeboer Dellelce LLP acted for CTI in connection with the RTO with a team including Geoffrey Cher, Niall Sweeney and Julian Lupo (Corporate/Securities) and Mariam Al-Shikarchy, Marija Tasevska and Emma Weiss (Tax).
Wildeboer Dellelce LLP will be legal counsel for Cytophage moving forward.
Latest News



